Cytomel (Liothyronine) Cost in South Dakota 2026

What Is Liothyronine and Why Do Some Patients Need It

Liothyronine is the synthetic form of triiodothyronine (T3), the biologically active thyroid hormone. Most clinicians prescribe levothyroxine (T4) first, but a measurable subset of patients on T4 monotherapy still report fatigue, cognitive slowing, and weight difficulty despite normal TSH values. For those patients, adding or substituting liothyronine may produce meaningful symptom relief. Bunevicius et al. (NEJM 1999, N=33) showed that a T4-plus-T3 combination improved mood, neuropsychological function, and general well-being compared with T4 alone, a finding that continues to shape prescribing debates today.

The drug has been FDA-approved since 1956. The current prescribing label covers hypothyroidism of any origin, pituitary TSH suppression in thyroid cancer, and myxedema coma. The FDA label for Cytomel lists standard starting doses of 25 mcg daily, titrated in 12.5 to 25 mcg increments every one to two weeks up to 75 mcg daily for most adults. Twice-daily dosing is common because T3's half-life of roughly one day produces a narrower serum peak than T4.

The American Thyroid Association's 2014 guidelines acknowledge combination T4/T3 therapy as an option for patients who remain symptomatic on T4 monotherapy, though the guidelines also note that further randomized evidence is needed before universal adoption. This nuanced stance means that payer coverage decisions vary widely by state and insurer, which directly affects what South Dakota patients pay out of pocket.

Thyroid disease is common. The CDC estimates that approximately 4.6% of Americans aged 12 and older have hypothyroidism, and the National Institutes of Health notes that women are five to eight times more likely than men to develop thyroid disorders. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH reports that about 10 million Americans take thyroid hormone replacement of some form. In South Dakota, with a population of roughly 910,000, that translates to tens of thousands of residents potentially eligible for liothyronine.

How Much Does Cytomel (Liothyronine) Cost in South Dakota in 2026

Generic liothyronine at South Dakota retail pharmacies costs approximately $35 per month on a cash-pay basis in 2026. Brand-name Cytomel carries a manufacturer list price of $120 per month. Compounded liothyronine from a licensed South Dakota 503A pharmacy costs about $40 per month.

The gap between Pfizer's $120 list price and the $35 generic cash price is substantial. Most patients who pay out of pocket have no clinical reason to choose brand Cytomel over the generic, because the FDA requires generic liothyronine to meet the same bioequivalence standards as the brand. FDA bioequivalence guidance defines the acceptable range as 80 to 125% of the reference product's area under the curve, a standard that all approved generic liothyronine manufacturers must meet.

GoodRx, RxSaver, and SingleCare coupons can push the generic price below $30 per month at chains like Walgreens, CVS, and Walmart in Sioux Falls and Rapid City. Prices vary by strength: 5 mcg tablets tend to cost slightly more per unit than 25 mcg tablets because manufacturers produce the higher-strength formulations in larger volumes. Patients prescribed 25 mcg twice daily should compare the per-tablet price at each pharmacy rather than assuming the closest location is cheapest.

A 2023 analysis published in JAMA Internal Medicine examining thyroid hormone pricing found that retail cash prices for T3-containing therapies varied by more than 300% across pharmacies within the same metropolitan area, underscoring the value of price-shopping even within a single South Dakota city. The same analysis noted that independent pharmacies occasionally offered lower prices than national chains for smaller-volume prescriptions.

Telehealth platforms serving South Dakota patients can transmit electronic prescriptions directly to local pharmacies or mail-order pharmacies licensed in the state, which may add shipping convenience without meaningfully altering the cash price.

Does South Dakota Medicaid Cover Liothyronine

South Dakota Medicaid does not cover Cytomel or generic liothyronine as an adjunct treatment for hypothyroidism in 2026. This is a significant coverage gap for the estimated 140,000 South Dakota residents enrolled in Medicaid as of 2024.

South Dakota operates Medicaid under a traditional fee-for-service model with a preferred drug list (PDL) administered through the South Dakota Department of Social Services. Levothyroxine appears on the PDL as the covered thyroid hormone replacement. Liothyronine is not listed as a preferred agent, and prior authorization for adjunct T3 therapy is not routinely approved for hypothyroidism. CMS Medicaid drug policy guidance allows states broad latitude to exclude drugs from coverage when a therapeutic alternative is available, which is the statutory basis South Dakota uses.

Patients with thyroid cancer who need TSH suppression may have a stronger medical necessity argument. The American Thyroid Association's guidelines on differentiated thyroid cancer management recommend T3 withdrawal or recombinant TSH stimulation before radioiodine scanning, a situation where liothyronine use is specifically protocol-driven rather than preference-based. Medicaid medical necessity appeals citing ATA protocol adherence have a higher (though still not guaranteed) approval rate in this indication.

Patients denied Medicaid coverage have three practical paths: pay the $35 generic cash price directly, use a manufacturer or third-party savings card, or ask their prescriber whether the clinical picture supports a formal prior authorization appeal.

Is Compounded Liothyronine T3 Legal in South Dakota

Compounded liothyronine T3 is legal in South Dakota when prepared by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. The cost runs approximately $40 per month, slightly above the generic retail price but meaningful for patients who need non-standard doses or slow-release formulations.

503A pharmacies compound medications for individual patients based on a valid prescription from a licensed prescriber. FDA 503A guidance distinguishes these patient-specific compounding pharmacies from 503B outsourcing facilities, which produce larger batches for healthcare institutions. In South Dakota, 503A pharmacies must be licensed by the South Dakota Board of Pharmacy and are subject to state inspection as well as federal oversight.

The clinical rationale for compounded liothyronine typically involves one of three scenarios. First, a patient may need a dose not commercially available (for example, 10 mcg or 37.5 mcg). Second, a patient may have allergies to excipients in brand or generic tablets. Third, some clinicians and patients prefer sustained-release liothyronine formulations, though the evidence for superior outcomes with slow-release T3 compared to immediate-release T3 is limited. Jonklaas et al. (Thyroid, 2014) reviewed pharmacokinetic data and noted that slow-release formulations reduce peak T3 serum concentrations, which may reduce palpitations in sensitive patients, but concluded that long-term outcomes data were insufficient to recommend them universally.

Compounded liothyronine is not FDA-approved, which means it lacks the bioequivalence data required of generic manufacturers. Patients choosing the compounded route should use pharmacies that perform routine potency and sterility testing and can share certificates of analysis on request.

The HealthRX.com clinical team uses the following decision framework when evaluating whether a South Dakota patient should use generic liothyronine versus compounded T3. Generic immediate-release is the default choice for patients starting T3 therapy, given lower cost and confirmed bioequivalence. Compounding becomes appropriate when the patient requires a non-available dose strength, has a documented excipient sensitivity, or has failed immediate-release T3 due to palpitations that a slow-release formulation may reduce. This framework is reviewed annually against updated ATA and Endocrine Society guidance.

Which Insurance Plans Cover Liothyronine in South Dakota

Coverage varies widely by insurer and plan tier in South Dakota. Most commercial plans place generic liothyronine on Tier 1 or Tier 2, resulting in copays between $5 and $35 per month. Brand Cytomel, when covered at all, typically sits on Tier 3 or Tier 4, with copays ranging from $40 to $90 per month even with coverage.

The largest commercial insurers operating in South Dakota include Wellmark Blue Cross Blue Shield of South Dakota, Sanford Health Plan, and Avera Health Plans. Each publishes an annual formulary. CMS guidance on formulary transparency requires Medicare Part D plans to make formulary information publicly accessible, and similar transparency is encouraged for commercial plans under the ACA. South Dakota patients can look up their specific plan's formulary at the insurer's website or call the member services number on their insurance card.

Medicare Part D coverage for liothyronine depends on the specific plan's formulary. Most Part D plans include generic liothyronine at Tier 1, meaning a typical copay of $0 to $10 per month. Patients in the coverage gap (the "donut hole") pay no more than 25% of the drug's cost under current law, per CMS Part D cost-sharing rules. Brand Cytomel is rarely covered at Tier 1 under Part D; patients prescribed brand should ask their prescriber whether a therapeutic substitution to generic is appropriate.

South Dakota state employee health plans, administered through the South Dakota Bureau of Human Resources, cover generic liothyronine. State employees pay standard generic copays, typically $10 to $20 per 30-day supply.

Employer-sponsored self-insured plans in South Dakota follow their own formularies. Patients on self-insured plans who face coverage denials can request a formulary exception citing medical necessity, particularly if they have documented intolerance to levothyroxine monotherapy or a clinical indication requiring T3 preparation before radioiodine therapy.

How Manufacturer and Third-Party Savings Programs Work in South Dakota

Pfizer's savings card for Cytomel can reduce brand-name costs for commercially insured patients who meet eligibility criteria. Patients without insurance or on Medicaid are not eligible for Pfizer's savings card under standard program terms, per manufacturer policy that excludes government-payer patients to comply with anti-kickback statutes.

For cash-pay patients, GoodRx, RxSaver, and Blink Health function as discount intermediaries. These programs negotiate rates with pharmacy benefit managers and pass a portion of the savings to the consumer. GoodRx reported average savings of 79% on generic prescriptions in a 2022 analysis. At South Dakota retail pharmacies, presenting a GoodRx coupon for generic liothyronine at the point of sale has consistently produced prices in the $20, $30 range for a 30-day supply of 25 mcg tablets.

NeedyMeds and the Partnership for Prescription Assistance list patient assistance programs (PAPs) through which Pfizer and generic manufacturers may supply liothyronine at no cost to uninsured patients meeting income thresholds. Income limits for most PAPs fall at or below 200 to 400% of the federal poverty level. In South Dakota, that corresponds roughly to an annual individual income of $29,000, $58,000 (based on 2024 federal poverty guidelines published by HHS).

"The best savings strategy for most uninsured patients is to combine a GoodRx or SingleCare coupon with a 90-day supply rather than a 30-day supply," notes the HealthRX.com clinical pharmacist team. A 90-day supply of generic liothyronine at many South Dakota pharmacies costs proportionally less per day than three separate 30-day fills, and some mail-order pharmacies price 90-day supplies at roughly double (not triple) the 30-day cash rate.

Can South Dakota Patients Get Liothyronine Via Telehealth

Telehealth prescribing of liothyronine is permitted in South Dakota. A licensed South Dakota prescriber or an out-of-state prescriber with a valid South Dakota medical license may conduct a telehealth evaluation and issue a liothyronine prescription electronically to a South Dakota pharmacy.

South Dakota enacted telehealth parity legislation that requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services. The Center for Connected Health Policy's 2023 state telehealth report confirmed South Dakota has both synchronous audio-video and asynchronous (store-and-forward) telehealth policies in place. This means a patient in a rural county such as Haakon or Ziebach, where endocrinologists are scarce, can consult a telehealth provider to initiate or continue T3 therapy without driving to Sioux Falls or Rapid City.

The prescribing workflow for liothyronine via telehealth typically includes a review of recent TSH, free T4, and free T3 labs; a symptom assessment; and confirmation that the patient has no contraindications such as untreated adrenal insufficiency or severe cardiovascular disease. The Endocrine Society's clinical practice guideline on hypothyroidism specifies that combination T4/T3 therapy should be initiated at low T3 doses and titrated based on symptom response and serum T3 levels, a protocol fully executable through telehealth follow-up.

DEA rules do not restrict liothyronine telehealth prescribing the way they restrict controlled substances. Liothyronine is not a Schedule II-V drug, so no Ryan Haight Act in-person visit requirement applies. A prescriber may initiate therapy based on a telehealth encounter and lab review alone.

Dosing, Safety, and Monitoring Considerations That Affect Cost Planning

Understanding dosing ranges matters for cost calculations because liothyronine is priced per tablet, not per mcg. A patient on 5 mcg twice daily uses 60 tablets per month. A patient on 25 mcg twice daily uses 60 tablets per month at the same count but a different strength. The per-tablet price at South Dakota pharmacies varies by strength, so patients should confirm pricing for their specific tablet strength.

Standard adult starting doses per the FDA-approved labeling begin at 25 mcg once daily for hypothyroidism, increasing by 12.5 to 25 mcg every one to two weeks. The maximum commonly prescribed dose is 75 mcg per day. Elderly patients and those with cardiovascular disease typically start at 5 mcg daily and titrate more slowly.

Monitoring on liothyronine includes serum free T3, free T4, and TSH at four to six weeks after each dose change, then annually once stable. The American Association of Clinical Endocrinology (AACE) clinical practice guidelines recommend keeping free T3 within the upper half of the reference range rather than relying on TSH alone when T3 is part of the regimen, because exogenous T3 suppresses TSH disproportionately. Lab costs for quarterly monitoring in South Dakota average $40, $80 per panel at independent labs such as Quest Diagnostics or LabCorp, and lower at federally qualified health centers (FQHCs) that use sliding-fee schedules.

Cardiac risk is the primary safety consideration. A meta-analysis published in Circulation (AHA) found that supraphysiologic thyroid hormone exposure is associated with atrial fibrillation risk, which is why dose titration above the physiologic T3 replacement range requires cardiac monitoring. This clinical requirement does not change the drug's cost, but it affects the total cost of care and should factor into shared decision-making with patients choosing between T4 monotherapy and combination therapy.

Liothyronine is contraindicated in untreated thyrotoxicosis, acute myocardial infarction uncomplicated by hypothyroidism, and as a weight-loss agent in euthyroid patients. The FDA drug safety communication database includes a warning against using thyroid hormones for obesity or weight management in euthyroid individuals, given the risk of serious or life-threatening toxicity.

Practical Steps for South Dakota Patients to Minimize Liothyronine Costs

South Dakota patients paying out of pocket should take four concrete steps. First, ask the prescriber for a generic liothyronine prescription rather than brand Cytomel. The generic at $35 per month saves $85 per month versus the brand list price. Second, compare prices at three to five pharmacies using GoodRx before filling. Prices across Sioux Falls pharmacies for the same generic can differ by $10, $15 per fill. Third, request a 90-day supply if the dose is stable; most pharmacies and mail-order services offer a per-day discount on 90-day fills. Fourth, check eligibility for Pfizer's savings card if on commercial insurance and prescribed brand Cytomel for a documented clinical reason.

Patients on South Dakota Medicaid who are denied coverage should document their prescriber's clinical rationale in writing, obtain a letter citing ATA or Endocrine Society guidelines, and file a formal prior authorization request through the South Dakota Department of Social Services pharmacy program. CMS guidance on Medicaid appeals requires that states process standard prior authorization requests within 14 calendar days.

Patients using telehealth platforms should confirm that the platform's affiliated pharmacy network includes at least one South Dakota-licensed mail-order pharmacy, as interstate mail-order requires a pharmacy license in the receiving state per NABP model pharmacy practice act standards.

Patients considering compounded liothyronine should verify that the South Dakota 503A pharmacy holds an active state license (searchable on the South Dakota Board of Pharmacy website) and voluntarily follows USP Chapter 795 standards for non-sterile compounding. The USP Chapter 795 standards set requirements for beyond-use dating, potency testing, and environmental controls that directly affect the reliability of each compounded dose.

At the standard dose of 25 mcg daily, generic liothyronine at the $35 South Dakota cash price costs approximately $1.17 per day, which remains below the $1.33 per day cost of compounded T3 at $40 per month.